Overexpression of the ERBB2 gene in human breast cancer is associated with a poor prognosis and resistance to hormonal treatment and chemotherapy. Oestrogen receptor (ER) positive tumour-derived cell lines are known to express relatively low levels of ERBB2 protein under oestrogenic conditions, but markedly higher levels following withdrawal of oestrogens or administration of tamoxifen. Expression of the closely related ERBB3 gene, which co-operates with ERBB2 in cellular transformation, is now shown to respond to oestrogenic manipulation in a similar way, both responses being mediated largely by transcriptional changes. Six previously undescribed DNase I hypersensitive sites occur within the ®rst intron of ERBB2 in cells that overexpress the gene. A 409 base pair DNA fragment containing one of these sites conferred ER dependent oestrogen inhibition on the ERBB2 promoter in two types of transient transfection assay. DNase I footprinting revealed four separate transcription factor binding sites within this fragment consistent with a role as a transcriptional enhancer. These ®ndings implicate intron 1 sequences in the control of ERBB2 expression for the ®rst time and demonstrate that one site within this region is involved in mediating the transcriptional response to oestrogens. Additionally, there is likely to be synergism between ERBB2 and ERBB3 signalling when both are overexpressed in response to oestrogen inhibition, thereby driving transformed cell behaviour.
Introduction
The ERBB2 proto-oncogene, which encodes a 185 kDa transmembrane tyrosine kinase, was identi®ed on the basis of its close similarity to the epidermal growth factor receptor (EGFR) gene (Coussens et al., 1985; King et al., 1985; Semba et al., 1985) . Two further related genes, ERBB3 Plowman et al., 1990) and ERBB4 (Plowman et al., 1993a) , have since been cloned, and encode receptors which can heterodimerise with ErbB2 to form high anity binding sites for the neuregulin ligands . ErbB2 is overexpressed in a proportion of human tumours arising from several dierent sites (Berchuck et al., 1990; Hall et al., 1990; Kern et al., 1990; Yokota et al., 1986; Yonemura et al., 1991) . In the breast, the 20 ± 25% of cancers which overexpress the gene have a poorer prognosis (Borg et al., 1990; Gasparini et al., 1992; Press et al., 1993; Slamon et al., 1987; Wright et al., 1989) and are relatively resistant to hormonal treatment (Wright et al., 1992) and chemotherapy (Gusterson et al., 1992; Muss et al., 1994) . In vitro, ERBB2 is a transforming oncogene, both in rodent ®broblasts (Di Fiore et al., 1987) and immortalised breast epithelial cell lines (D'Souza et al., 1993) . In contrast, ERBB3 does not induce cellular transformation on its own; it does, however, co-operate with ERBB2 in this process. Cotransfection of ERBB3 with ERBB2 increases the number of transformation events by an order of magnitude (Alimandi et al., 1995) . ErbB3 is also overexpressed in breast cancer (Gasparini et al., 1994) , and both genes are upregulated at the level of transcription (Hollywood and Hurst, 1993; Skinner and Hurst, 1993) , but unlike ERBB2, overexpression of ERBB3 is not associated with gene ampli®cation (Lemoine et al., 1992) .
Approximately 60% of breast cancers express oestrogen receptor (ER), and these tumours are less likely to overexpress ERBB2 (Adnane et al., 1989; Borg et al., 1990; Tandon et al., 1989) . Tamoxifen is the leading hormonal treatment for breast cancer, producing objective disease responses in women with metastatic breast cancer (Hayward et al., 1977) and, in the adjuvant setting, increasing overall survival in post-menopausal women (Early Breast Cancer Trialists Collaborative Group, 1992a,b) . In women at high risk of breast cancer, tamoxifen has been given prophylactically with the aim of reducing the incidence of the disease (Powles et al., 1990) . The widespread use of tamoxifen, especially in healthy women, makes a clear understanding of its action particularly important. In ER positive breast cancer cell lines, tamoxifen or oestrogen withdrawal have been shown to increase ERBB2 expression (Dati et al., 1990; Read et al., 1990; Russell and Hung, 1992) , and this may be an undesirable consequence of tamoxifen treatment, given the association between high ERBB2 expression and poor prognosis. There is therefore good reason to investigate the mechanisms behind this phenomenon. If it were possible to separate antioestrogenic action from the eect on ERBB2 expression, potentially more eective drugs could be developed.
In this paper, the chromatin structure of the ERBB2 gene within overexpressing breast cells is shown to be complex, with six DNAse I hypersensitive sites occurring in the ®rst intron. One of these sites includes a transcriptional enhancer which we show can confer oestrogen suppression upon the ERBB2 promoter. Additionally, expression of ERBB3 is shown to vary with oestrogenic manipulation in the same manner as ERBB2 and this response is also mediated by changes in transcription rate. The potential importance of these observations to the pathogenesis of breast cancer is discussed.
Results

Oestrogens reduce ERBB2 and ERBB3 expression
The eect of hormonal manipulation on gene expression in the ER positive ZR75-1 breast cancer cell line was analysed by Northern blotting (Figure 1 ). As shown previously (Dati et al., 1990; Read et al., 1990; Russell and Hung, 1992; Warri et al., 1991) , ERBB2 mRNA, which is present at moderate levels in cells grown in normal, oestrogenic media (lane 1), was more abundant in cells grown in oestrogen depleted media (lane 2). A similar increase was seen in the presence of the pure oestrogen antagonist, ICI 182780 (lane 4). The eect of ICI 182780 in this system resembles that of the partial oestrogen antagonist, tamoxifen (data not shown). In contrast, ERBB2 mRNA expression was markedly reduced by the addition of exogenous b-oestradiol to oestrogen depleted media (lane 3). The dierence in ERBB2 mRNA levels between oestrogenic (lane 3) and antioestrogenic (lane 4) media was ®vefold as measured by densitometry. The expression of the related ERBB3 gene followed a similar pattern, with low expression under oestrogenic conditions (lanes 1, 3 and 5), and higher expression when oestrogen was either absent or antagonised (lanes 2 and 4), although the overall response (3.5-fold) was less marked than for ERBB2. In contrast, no change in EGFR mRNA expression was found under these conditions. ERBB4 mRNA is not expressed at detectable levels in the ZR75-1 cell line. Expression of the oestrogen dependent pS2 gene (Brown et al., 1984) was only detected in cells grown under oestrogenic conditions (lanes 1, 3 and 5), thus con®rming that the intended hormonal manipulations had been achieved. A similar analysis performed with the ER negative cell line MDA MB 453 showed no change in ERBB2 or ERBB3 expression levels (data not shown).
Oestrogen reduces ERBB2 and ERBB3 transcription
In order to determine whether the changes in ERBB2 and ERBB3 mRNA levels were transcriptionally mediated, nuclear run-on assays were performed using ZR75-1 cells grown in either 10 78 M b-oestradiol or 10 76 M tamoxifen (Figure 2 ). Speci®c in vitro generated transcripts were detected by hybridisation to immobilised single stranded cDNA. As expected, there was minimal hybridisation to the sense DNA strands or to the pBluescript vector. 76 M tamoxifen for 48 h were used in nuclear run-on assays to generate radiolabelled, nascent RNA. This was hybridized to sense and antisense single stranded cDNAs of the indicated genes, or to a plasmid vector control and the resulting autoradiograph is shown phosphate dehydrogenase (GAPDH) transcription was identical in the dierent hormonal environments, but the rates of ERBB2 and ERBB3 transcription were respectively three-and 3.5-fold higher in the presence of tamoxifen than in the presence of b-oestradiol. This change in ERBB2 transcription rate is consistent with that previously described (Antoniotti et al., 1994) and accounts for an important part of the overall change in ERBB2 expression observed on Northern blots (see Figure 1 ). It is likely that some post-transcriptional mechanisms also operate, as the change in ERBB2 transcription rate is not quite sucient to explain completely the increase in mRNA level (threefold versus ®vefold). In contrast, the increase in ERBB3 transcription rate, which has not been previously reported, is identical to the change in overall mRNA levels ( Figure 1 ).
DNase I hypersensitive sites are found in the ®rst intron of ERBB2 Regulatory sites within mammalian genes are characterised by an open chromatin conformation and increased sensitivity to endonuclease digestion. A DNase I hypersensitive site assay was used to locate potential regulatory sites for ERBB2. As the related EGFR gene has been shown to have regulatory elements within the ®rst intron (Chrysogelos, 1993) , the equivalent region in ERBB2 was chosen for investigation. The result of one DNase I hypersensitive site assay is shown in Figure 3a . Here, genomic DNA puri®ed from ZR75-1 cell nuclei treated with increasing concentrations of DNase I was restricted with HindIII, subjected to Southern blotting, and probed with a DNA fragment which labels the 5' end of a 4.6 kb HindIII intron 1 restriction fragment (see Figure 3b) . The extra bands which appear in lanes carrying more heavily DNase I digested DNA indicate the presence of DNase I hypersensitive sites. The position of each site within the gene was determined from the electrophoretic mobility of the band; the 1.2 kb band in Figure 3a , for example, represents a DNase I hypersensitive site 1.2 kb downstream from the 5' HindIII site. The positions of these bands, and of those mapped to the 3' end of the intron, were con®rmed using further probes and also similar assays using EcoRI restricted DNA. All the sites identi®ed within intron 1 by these assays are shown on the restriction map in Figure 3b . A site over the region of transcription initiation was also identi®ed, in agreement with a previous report (Scott et al., 1994) . No further DNase I hypersensitive sites were detected in approximately 8 kb of DNA downstream of exon 2, but a single site was located approximately 6 kb upstream of the transcriptional start site (data not shown). Assays using cells grown in 10 76 M tamoxifen showed an identical pattern of DNase I hypersensitivity (data not shown), suggesting that the chromatin structure is not altered by oestrogenic manipulation. However, the potential importance of these sites as gene regulatory elements was highlighted by the ®nding that in an ERBB2 low-expressing cell line, MDA MB 231, all of the intron 1 hypersensitive sites, but not the one over the transcription initiation site, were absent (data not shown).
An intron 1 element mediates oestrogen-induced suppression of promoter activity
In order to localise regions of the ERBB2 gene responsible for mediating oestrogen induced repression, reporter gene constructs driven by three dierent lengths of ERBB2 upstream sequence were transiently transfected into ZR75-1 cells. Chloramphenicol acetyl transferase (CAT) reporter activity was measured in the presence of b-oestradiol or tamoxifen ( Figure 4 ) and the ratio of activities in the two dierent media was determined. All the constructs gave higher reporter activity under oestrogenic conditions, indicated by an activity ratio (tamoxifen/oestradiol) of less than 1. This is the opposite response to that of the endogenous gene, indicating that in this experimental system DNA sequences mediating oestrogen-induced suppression of transcription are not sited within the 6 kb of upstream DNA examined. Nuclei from ZR75-1 cells were treated with increasing amounts of DNase I and the genomic DNA was isolated, restricted with HindIII, separated on a 0.7% agarose gel and blotted to nylon membrane. The autoradiograph shows the result of hybridization with the 1 kb genomic fragment (indicated by the shaded box in the diagram below) which produces a hybridizing band of 4.6 kb. Extra bands, generated by the action of DNase I, are indicated by arrows. The band denoted by an asterisk, which is insensitive to DNase I digestion, is likely to represent cross-hybridization to another genomic fragment; hybridization with other probes did not generate this band (data not shown In contrast, when the 4.6 kb HindIII intron 1 restriction fragment (see Figure 3b ) was cloned into p300CAT in either orientation, oestrogen suppression of reporter activity was seen (data not shown). This observation indicated the presence of an oestrogen repressible enhancer and by performing similar experiments with constructs containing dierent subfragments of the 4.6 kb HindIII fragment ( Figure 5 ), oestrogen induced repression was localised to a 409 bp XbaI ± StuI fragment. When this fragment was incorporated into the p300CAT reporter construct, CAT activity increased by a factor of 1.8 in tamoxifen, compared to a decrease to 0.85 seen with p300CAT under the same conditions, giving an overall change in activity ratio (tamoxifen/oestradiol) of 2.1 (Figure 4 ). Further division of this fragment either to a PstI site or to an internal DdeI fragment (see Figure 5 ) led to total loss of oestrogen suppression. The XbaI ± StuI fragment is located 4 kb downstream of the start of transcription and one of the intron 1 DNase I hypersensitive sites maps within it (see Figure 3b) , indicating that DNA in this region is likely to be accessible to transcription factors in the intact cell, and thus able to act as an enhancer in vivo.
Repression requires the presence of oestrogen receptor
When the p300/Xba/Stu reporter construct was transfected into the ER negative MDA MB 453 cell line, reporter activity was independent of oestrogenic manipulation ( Figure 6, columns 1 and 3) . If the ER expression plasmid pHEGO was co-transfected however, reporter activity was reduced by a factor of 3 in an oestrogenic environment, a suppression which was reversed by addition of ICI 182780 ( Figure 6 , columns 2 and 4). Although the two experiments are not directly comparable, it is striking that the change in transcriptional activity found here was of a similar magnitude to that observed in the nuclear run-on assay (Figure 2 ). This therefore further supports the idea that the key sequences mediating oestrogen repression of ERBB2 transcription lie within the Xba/Stu intron 1 element. The experiment in Figure 6 also con®rms that oestrogen-induced suppression of reporter activity is dependent upon the presence of oestrogen receptor.
DNase I footprinting demonstrates four protein binding sites within the XBaI ± StuI fragment The XbaI ± StuI fragment has been sequenced on both strands using standard chain termination techniques (Figure 7) . The sequence is not homologous to any other on the sequence databases and does not contain Figure 4 Oestrogen repression of ERBB2 promoter activity is mediated by an intron 1 element and not by 5'¯anking sequences. Three reporter plasmids containing dierent lengths of ERBB2 upstream sequence (p300CAT, p2000CAT and p6000CAT) and one including the 409 bp XbaI ± StuI intron 1 fragment (p300/ Xba/Stu; see Figure 3 ) were constructed as indicated in the diagram. The activity of each reporter was measured after transfection into ZR75-1 cells which were subsequently grown in the presence of either 10 78 M b-oestradiol or 10 76 M tamoxifen. Duplicate 9 cm plates were each transfected with 2.5 mg of reporter. The results are presented as the mean activity ratio (tamoxifen/b-oestradiol) in the two media, plus one standard error of the mean Figure 5 Oestrogen repression of ERBB2 promoter activity is mediated by intron 1 fragments. The 4.6 kb HindIII ERBB2 intron 1 fragment (see Figure 3b ) is shown together with a series of subfragments which have all been assessed for oestrogen repression activity in transient transfection assays after cloning into p300CAT (see Figure 4) . The three fragments which mediated oestrogen repression are indicated with asterisks a consensus oestrogen response element (ERE), suggesting that oestrogen receptors do not bind directly to this sequence. Although synergy between several half-palindromic TGACC motifs has been shown to permit ER binding and ERE function (Kato et al., 1992) , only a single half-palindromic motif has been identi®ed in this sequence (Figure 7) , and this does not bind ZR75-1 nuclear proteins ( Figure  8 ). DNase I footprinting was used to determine sites of transcription factor binding to the XbaI ± StuI fragment. The fragment was labelled at the 3' end and used as a probe in incubations with crude nuclear extracts from ZR75-1 cells grown in the presence of either 78 M b-oestradiol or 10 77 M ICI 182780 for 48 h. Four regions (A ± D) of DNA were found which were protected from DNase I digestion when compared with control reactions digested without prior incubation with nuclear extract (Figure 8 ; compare lanes 2,3,5 and 6 with lanes 4 and 7). The positions of these four protected regions are also indicated on the DNA sequence (Figure 7 ). There was no apparent dierence between the protection patterns obtained with nuclear extracts derived from cells grown in oestrogenic or anti-oestrogenic conditions. The positions of these footprints was con®rmed by a similar experiment using a probe labelled at the 5' end (data not shown).
Discussion
Several groups have reported an increase in ERBB2 mRNA and protein levels in cultured ER positive human breast cancer cells following oestrogen deprivation or treatment with anti-oestrogenic drugs (Dati et al., 1990; Read et al., 1990; Russell and Hung, 1992; Warri et al., 1991) . Similar results have also been obtained with ZR75-1 cells grown as xenografts in nude mice (Warri et al., 1991) . In this report we show that ERBB3 expression is also repressed by boestradiol and upregulated by oestrogen inhibition (Figure 1) . However, whereas for ERBB2 the increase in gene transcription rate does not entirely account for the rise in mRNA levels, the increased ERBB3 gene transcription rate observed by nuclear run on assay (Figure 2) completely accounts for the changes in mRNA levels in the presence of antioestrogens. The ®nding that ERBB2 and ERBB3 are similarly upregulated in the presence of antioestrogens is signi®cant as this is likely to have a synergistic eect on cell behaviour. In ®broblast transformation assays, ERBB2 is only transforming when expressed at high levels similar to those found in breast cancer cell lines with ERBB2 gene ampli®cation (Di Fiore et al., 1987) . On the other hand, ERBB3 does not cause transformation at any level of expression when transfected in isolation. If, however, the two genes are co-transfected, they readily elicit transformation under conditions in which neither gene alone is transforming, at expression levels achievable by upregulation of transcription alone without a requirement for gene ampli®cation (Alimandi et al., 1995) . It is likely, then, that the combined overexpression of ERBB2 and ERBB3 which occurs in the presence of antioestrogens, although relatively modest, is a more powerful oncogenic stimulus than overexpression of ERBB2 alone. This ®nding is possibly related to the biochemistry of the two receptors. The ERBB3 tyrosine kinase domain lacks several critical amino acid residues and has impaired functional activity in some (Guy et al., 1994) , but not all systems (Prigent and Gullick, 1994) . ERBB2 has an active tyrosine kinase, but does not itself bind the neuregulin ligands (Plowman et al., 1993b) . Heterodimers of the two receptors, however, can interact with neuregulins with high anity, resulting in increased tyrosine kinase activity and activation of intracellular signal transduction pathways .
Although post-transcriptional mechanisms must contribute to the change in ERBB2 mRNA levels in the dierent oestrogenic conditions, clearly the majority of the eect is due to an alteration in gene transcription rate (threefold versus a ®vefold change in mRNA level; Figures 1 and 2 ). In this report we demonstrate that this oestrogen repression of ERBB2 transcription is mediated by an enhancer that maps within the ®rst intron of the gene. This enhancer is able to repress expression from the ERBB2 proximal promoter in oestrogenic conditions in ER positive breast cells (Figure 4 ) and in ER negative cells when additionally transfected with an ER expression plasmid (Figure 6) .
Consequently, two dierent types of transfection assay used here demonstrate the importance of this intronic element for oestrogen repression, whereas examining up to 6 kb of¯anking sequence failed to reveal an oestrogen regulated element 5' of the transcription start site (Figure 4 ). This contrasts with two previous reports (Antoniotti et al., 1994; Russell and Hung, 1992) where promoter activity did appear to be suppressed by oestrogens. It is likely, however, that this re¯ects dierences in the experimental systems used. One study employed NIH3T3 mouse ®broblasts and CV-1 monkey ®broblasts (Russell and Hung, 1992) and the distinct behaviour of the ERBB2 promoter here may re¯ect dierences in species and tissue of origin between these and human breast cancer cells. The second experimental system, using the ER positive T47D breast cancer cell line, is similar to the one described here (Antoniotti et al., 1994) , but significantly transcriptional repression by oestrogens could only be shown when an ER expression plasmid was additionally co-transfected. The results shown here for the XbaI ± StuI fragment in ZR75-1 cells (Figure 4) are the ®rst demonstration of a reduction in transcriptional activation by any part of the ERBB2 gene in response to oestrogen binding by endogenous receptors. Interestingly, we have also been unable to identify an element mediating oestrogen represssion within 5 kb of ERBB3 5'¯anking sequences (unpublished data). Currently we are cloning intronic regions of this gene with a view to mapping DNase I hypersensitive sites and testing for enhancer activity.
The precise molecular mechanism by which the ERBB2 intron 1 enhancer mediates oestrogen induced suppression of gene transcription is not yet clear. Four footprinted regions have been identi®ed within this element (Figure 8 ), but as the footprinting pattern is invariant with oestrogen manipulation, it is unlikely that the eect is mediated by major changes in the abundance of a DNA binding transcription factor. Truncation of the XbaI ± StuI fragment to the internal PstI site (thus disrupting footprint C and removing the region equivalent to footprint D) led to the loss of oestrogen repression activity ( Figure 5 ). However, a sequence including both footprints C and D alone was also not sucient to mediate oestrogen repression (DdeI fragment, Figure 5 ). Taken together these observations indicate that no single small region within the XbaI ± StuI fragment is sucient to mediate oestrogen repression and suggest that proteins bound to all four footprinted regions need to be present to permit normal functioning of the enhancer. In the absence of a recognised ERE, any mechanism involving ER directly binding to the XbaI ± StuI fragment is unlikely. One possibility is that ER is interacting at a protein-protein level with one, or more, of the bound transcription factors and inhibiting transactivation. This type of interaction has been described in other systems; the glucocorticoid receptor interaction with AP1 being one example (Schule and Evans, 1991) . Jun and Fos, but not Jun D, are known to inhibit the transactivation function of ER (Doucas et al., 1991) . Conversely, NF-kB and C/EBPb transactivation is inhibited by ER protein-protein binding at the interleukin 6 promoter (Stein and Yang, 1995) . An indirect interaction could also occur if a coactivator protein such as p300 or CREB binding protein (CBP) were required for activity of this enhancer. Nuclear receptors are known to compete with AP-1 for CBP (Kamei et al., 1996) , which is reported to be limiting within cells, and similar competition for a coactivator would explain the experimental ®ndings described here. Another potential mechanism would be post-translational modification of transcription factors in response to oestrogen manipulation, leading to changes in transactivation activity but not in DNA binding. Distinguishing between these possibilities awaits the positive identification of these DNA binding transcription factors from among the many potential candidates revealed by a database search, a process which is currently under way.
In view of the importance of ERBB2 overexpression in breast cancer, several groups have investigated mechanisms by which transcription of the gene can be upregulated (Chen and Gill, 1994; Grooteclaes et al., 1994; Hollywood and Hurst, 1993; Miller et al., 1994; Sarkar et al., 1994; Scott et al., 1994) . All studies to date have focused on the region of DNA upstream of the transcriptional start site. The demonstration here that the ERBB2 ®rst intron contains potential transcriptional regulatory regions (Figure 3 ) means that the search for DNA binding factors which lead to overexpression should be extended to cover this region as well. Intron 1 DNase I hypersensitive sites have been demonstrated in the EGFR gene, and their appearance in dierent cell lines correlates with the expression status of the gene (Chrysogelos, 1993) . It is possible that a similar relationship will be seen for ERBB2. Intriguingly, the MDA MB 231 cell line, which only expresses ERBB2 at a low level, does not have any of the intron 1 DNase I hypersensitive sites seen in overexpressing cells (unpublished results) . If this ®nding is con®rmed in a broader range of cell lines it will assist in the search for further determinants of overexpression.
Materials and methods
Cells and cell culture
ZR75-1 cells (ERBB2/3 overexpressor, ER+ve) were maintained in RPMI+10% fetal calf serum (FCS) and transferred to Dulbecco's Modi®ed Eagle's Medium (DMEM)+10% FCS before transfection or hormonal manipulation. MDA MB 453 (ERBB2/3 overexpressor, ER7ve) and MDA MB 231 (ERBB2/3 low expressor, ER7ve) cells (ATCC) were grown in DMEM+10% FCS. Oestrogen depleted FCS was prepared by two successive incubations with dextran-charcoal slurry at 558C (Darbre et al., 1983) and used in phenol red-free DMEM. boestradiol (Sigma) and ICI 182780 (Zeneca Pharmaceuticals) were stored as 0.01 M solutions in ethanol at 7208C. Tamoxifen citrate (Sigma) was stored at 7 mM in 70% ethanol at 7208C.
Northern blots
Total RNA prepared from subcon¯uent cells using the Qiagen RNeasy kit was separated on 1% agarose formaldehyde gels, capillary blotted onto positively charged nylon membrane (Hybond N + , Amersham) in 206SSC and u.v. crosslinked. Membranes were prehybridized and hybridized in aqueous buer (56SSC, 56Denhardt's solution, 20 mM sodium phosphate pH 7, 1 mg/ml torula RNA (Sigma) and 1% sodium dodecyl sulphate (SDS) and probed with the following labelled cDNA fragments: EGFR (Ullrich et al., 1984) , ERBB2 , ERBB3 (Plowman et al., 1990) , ERBB4 (Plowman et al., 1993a) , pS2 (Jakowlew et al., 1984) and rat glyceraldehyde phosphate dehydrogenase (GAPDH) (Tso et al., 1985) . Membranes were washed to 0.56SSC+0.1% SDS at 658C and autoradiographed at 7758C. Autoradiographs were scanned using a Molecular Dynamics Personal Densitometer Si.
Nuclear run-on assays
ZR75-1 cells were grown in either 10
78 M b-oestradiol or 10 76 M tamoxifen for 48 h and their nuclei prepared by detergent lysis of the cell membrane and centrifugation through a sucrose cushion. In vitro transcription and puri®cation of labelled RNA were carried out as previously described (Roberts and Bentley, 1992) . Speci®c transcripts were detected by hybridization to sense and antisense single stranded cDNAs, prepared using the phage rescue technique (Stratagene) and immobilised on positively charged nylon membranes (Hybond N + , Amersham). Equal activities of labelled RNA were used in each hybridization.
Membranes were washed to 0.26SSC+0.1% SDS at 658C before autoradiography. Quantitation was achieved by laser densitometry, as above.
DNase I hypersensitive site assay
Nuclei were isolated from ZR75-1 cells by detergent lysis of the cell membrane. Aliquots were incubated with DNase I (Worthington) at concentrations of 0 to 100 mg/ml for 10 min at 378C. Genomic DNA was puri®ed by proteinase K digestion, phenol/chloroform extraction and ethanol precipitation.
Hypersensitive sites were demonstrated by Southern blotting of restricted DNA, and hybridization with radiolabelled ERBB2 genomic DNA fragment probes derived from the ln2 phage (Tal et al., 1987) . The size of each band was determined by comparison of its electrophoretic mobility with that of standard markers (1 kb ladder, Life Technologies).
Preparation of reporter constructs ERBB2 upstream sequence fragments extending from the SmaI site at +40 bp to 7300, 72000 and 76000 bp, numbering from the major transcriptional start site (Tal et al., 1987) , were cloned into pCAT Basic (Promega) to generate p300CAT (Hollywood and Hurst, 1993) , p2000CAT and p6000CAT (Figure 4) . In order to assess intron 1 fragments for enhancer activity, they were cloned into the p300CAT construct (Figure 4 ).
Transient transfection assays
Cells at approximately 30% con¯uence were transfected using a calcium phosphate precipitation method as previously described (Bates and Hurst, 1996) . Precipitates were left on the cells overnight and then removed by washing in phosphate buered saline (PBS). Hormonal manipulation started after the wash, hence cells in either arm of each experiment were transfected under identical conditions. Subcon¯uent cells were harvested 48 h after addition of hormones. Where indicated, the ER expression plasmid pHEGO (Tora et al., 1989) was cotransfected. The b-galactosidase expression construct pCH110 (Pharmacia) was routinely co-transfected and CAT results are presented after correction for b-galactosidase activity. CAT and bgalactosidase activities were measured using standard protocols (Bates and Hurst, 1996) . b-galactosidase assay values did not vary signi®cantly between cells grown in oestrogenic media and those grown in the presence of antioestrogen. Each experiment was performed on three separate occasions on duplicate plates of cells.
DNase I footprinting
The XbaI ± StuI genomic DNA fragment probe was generated by labelling the strand shown in Figure 7 at the StuI (3') end with a 32 P-dATP. Labelled probe (7 fmol) was incubated with crude nuclear extract, prepared as described (Dignam et al., 1983) prior to partial digestion with DNase I (Worthington). After proteinase K digestion, phenol/chloroform extraction and ethanol precipitation, equal counts were loaded in each lane of a denaturing acrylamide gel, together with an A+G chemical degradation sequencing ladder prepared from the same probe and control DNase I digests of probe alone.
